Jakub Turek

Jakub Turek

Auto-generated profile, based on publicly available information

Jakub Turek

The Lower Silesia Center of Heart Diseases MEDINET, Wrocław, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in The Journal of Vascular Access
Verified
Journal Article
Closed access
AVAn S De Vriese
An S De Vriese
ADAnnick D’hAeninck
Annick D’hAeninck
AMArtur Mendes
Artur Mendes
AMAugusto Ministro
Augusto Ministro
DKDainis Krievins
Dainis Krievins
MGMauro Gargiulo
Mauro Gargiulo
Background: Arteriovenous grafts (AVGs) are used for patients deemed unsuitable for the creation of an autogenous arteriovenous fistula (AVF) or unable to await maturation of the AVF before starting hemodialysis. However, AVGs are prone to infection and thrombosis resulting in low long-term patency rates. The novel aXess Hemodialysis Graft consists of porous polymeric biomaterial allowing the infiltration by cells and the growth of neotissue, while the graft itself is gradually absorbed, ultimately resulting in a fully functional natural blood vessel. The Pivotal Study will examine the long-term effectiveness and safety of the aXess Hemodialysis Graft. Methods: The Pivotal Study is a prospective, single-arm, multicenter study that will be conducted in 110 subjects with end-stage renal disease who are not deemed suitable for the creation of an autogenous vascular access. The primary efficacy endpoint will be the primary patency rate at 6 months. The primary safety endpoint will be the freedom from device-related serious adverse events at 6 months. The secondary endpoints will include the procedural success rate, time to first cannulation, patency rates, the rate of access-related interventions to maintain patency, the freedom from device-related serious adverse events and the rate of access site infections. Patients will be followed for 60 months. An exploratory Health Economic and Outcomes Research sub-study will determine potential additional benefits of the aXess graft to patients, health care institutions, and reimbursement programs. Discussion: The Pivotal study will examine the long-term performance and safety of the aXess Hemodialysis Graft and compare the outcome measures with historical data obtained with other graft types and autogenous AVFs. Potential advantages may include superior long-term patency rates and lower infection rates versus currently available AVGs and a shorter time to first cannulation compared to an autologous AVF. As such, the aXess Hemodialysis Graft may fulfill an unmet clinical need in the field of hemodialysis access.

22 September 2026 in The Journal of Vascular Access
Verified
Journal Article
Closed access
KTKacper Turek
Kacper Turek
MMMaciej Malinowski
Maciej Malinowski
JTJakub Turek
Jakub Turek
ŁDŁukasz Dzieciuchowicz
Łukasz Dzieciuchowicz
This paper describes a technique used to treat an end-stage kidney disease patient, a kidney transplant recipient, who was diagnosed with an advanced aneurysmal degeneration of the brachial artery. The current report presents a novel, staged technique of surgical vascular repair with a previously arterialized autologous great saphenous vein (GSV), along with a 12-month follow-up observation period. The patient was treated with an arterialised great saphenous vein bypass that was not primarily suitable for use as a conduit due to its small diameter. To achieve a satisfactory vessel size, an arteriovenous fistula was created, resulting in the maturation and arterialisation of the outflow vein.